Y-mAbs Therapeutics, Inc represents values of dedication, innovation, and patient-centered care. As a biopharmaceutical company, Y-mAbs is committed to developing and commercializing novel antibody-based therapies to address unmet medical needs in pediatric and adolescent patients. Their corporate philosophy emphasizes cutting-edge research, scientific expertise, and a relentless pursuit of improving patients' lives. With a focus on oncology and neuroblastoma, Y-mAbs strives to bring transformative treatments to those in need. Through their dedication to scientific advancements and patient-centric approach, Y-mAbs Therapeutics, Inc aims to make a positive impact on the lives of individuals affected by these diseases.

Y-mAbs Therapeutics, Inc primarily operates in the United States.

Y-mAbs Therapeutics, Inc has achieved several significant milestones. The company obtained accelerated approval from the U.S. FDA for naxitamab in March 2020, for the treatment of high-risk neuroblastoma in pediatric patients aged 1 year and above. Furthermore, Y-mAbs Therapeutics, Inc successfully completed a rolling submission of a Biologics License Application (BLA) in October 2020, seeking full approval for naxitamab, a monoclonal antibody. These achievements highlight the company's commitment to developing innovative therapies for pediatric patients with high-risk neuroblastoma and their dedication to obtaining necessary regulatory approvals. Y-mAbs Therapeutics, Inc's milestones demonstrate their progress in advancing effective medical solutions in the field of oncology.

Y-mAbs Therapeutics, Inc is a biopharmaceutical company specializing in the development and commercialization of innovative antibody-based therapies. Established in 2015, Y-mAbs focuses on developing treatments for pediatric and adult oncology and neuroblastoma. The company's mission is to provide patients with severe diseases access to new and effective treatment options. With a strong emphasis on research and development, Y-mAbs has built a robust pipeline of promising therapies. Led by a team of experienced professionals, Y-mAbs continues to strive for advancements in healthcare and improved patient outcomes. As a leader in the biopharmaceutical industry, Y-mAbs Therapeutics, Inc remains dedicated to making a positive impact on the lives of patients worldwide.

The main competitors of Y-mAbs Therapeutics, Inc in the market include companies such as Novartis AG, Roche Holding AG, AstraZeneca PLC, Pfizer Inc., and Bristol-Myers Squibb Company.

Y-mAbs Therapeutics, Inc is primarily active in the biotechnology and pharmaceutical industries.

Y-mAbs Therapeutics, Inc. has a specialized business model focused on developing and commercializing innovative antibody-based therapies. As a clinical-stage biopharmaceutical company, Y-mAbs Therapeutics primarily focuses on discovering, developing, and delivering targeted treatments for pediatric cancers. By harnessing the power of antibodies, Y-mAbs Therapeutics aims to address the unmet medical needs of children with cancer and improve their chances of survival and quality of life. Through strategic partnerships, research, and a patient-centered approach, Y-mAbs Therapeutics aims to revolutionize pediatric oncology and make a significant impact in the field of cancer therapeutics.

P/E odnos Y-mAbs Therapeutics iznosi -17,92.

KUV kompanije Y-mAbs Therapeutics iznosi 5,77.

AlleAktien kvalitativni skor za Y-mAbs Therapeutics je 2/10.

očekivana Y-mAbs Therapeutics promet je 90,23 mil. USD.

Dobit očekivana Y-mAbs Therapeutics je -29,04 mil. USD.

Y-mAbs Therapeutics, Inc. is a biopharmaceutical company focused on developing novel cancer drugs specifically targeted to the needs of children and adults with rare, aggressive, and often deadly forms of cancer. The company was founded in 2015 by experienced biotech leaders and has been supported by a variety of private and public financings. Y-mAbs Therapeutics specializes in the development and commercialization of therapeutic antibodies for the treatment of cancer. Their business model focuses on identifying and developing first-in-class or best-in-class therapeutic antibodies that have high efficacy and minimal side effects. The company utilizes advanced technologies and innovative research models to achieve this. Y-mAbs Therapeutics' product pipeline consists of several products in different stages of clinical development. The main antibody in their pipeline is Danyelza (Naxitamab-gqgk), which is used for the treatment of pediatric neuroblastoma. Another antibody in their pipeline is Omburtamab, which is used for the treatment of brain metastases in neuroblastoma patients. In addition to the development of therapeutic antibodies, Y-mAbs Therapeutics also offers diagnostic procedures based on the detection of cancer cell markers. These diagnostic procedures enable early detection of cancer and precise diagnosis of the disease. Y-mAbs Therapeutics' business model strongly focuses on collaboration with other companies and research institutions. The company collaborates with leading clinical facilities and academies to accelerate the development and commercialization of its products. Additionally, the company has entered into several partnerships and licensing agreements with pharmaceutical companies to accelerate the development and commercialization of its products. Y-mAbs Therapeutics aims to expand its global presence. The company plans to market its products in the United States and Europe, seeking approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the company plans to market its products in Asia and other regions. In summary, Y-mAbs Therapeutics' business model is based on the development and commercialization of novel cancer drugs targeted to the needs of patients with rare and aggressive forms of cancer. The company utilizes advanced technologies and innovative research models to improve the efficacy and safety of its products. Additionally, the company emphasizes collaboration and partnerships with other companies and research institutions to expand its global presence and accelerate the development and commercialization of its products.

Y-mAbs Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Y-mAbs Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Y-mAbs Therapeutics je US9842411095.

WKN od Y-mAbs Therapeutics je A2N5R0.

Oznaka za praćenje akcija kompanije Y-mAbs Therapeutics je YMAB.

U poslednjih 12 meseci, Y-mAbs Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Y-mAbs Therapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Y-mAbs Therapeutics trenutno iznosi .

Y-mAbs Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Y-mAbs Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Y-mAbs Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Y-mAbs Therapeutics od 30. 11. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 30. 11. 2024..

Isplata poslednje dividende izvršena je 30. 11. 2024..

U godini 2023 kompanija Y-mAbs Therapeutics je isplatila 0 USD kao dividende.

Dividende od Y-mAbs Therapeutics se isplaćuju u USD.